Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nexstim OyjOHEL:NXTMH +8.22%61 FCF Margin % is -16.73% as of Jun. 2026. GuruFocus rates OHEL:NXTMH with a GF Score™ of 61/100 and a GF Value™ of €9.38 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Nexstim Oyj ranks worse than 55.91% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nexstim Oyj's Free Cash Flow for the
six
months ended in Jun. 2026 was €-0.88 Mil. Nexstim Oyj's Revenue for the
six
months ended in Jun. 2026 was €5.23 Mil. Therefore, Nexstim Oyj's FCF Margin % for the quarter that ended in Jun. 2026 was -16.73%.
The historical rank and industry rank for Nexstim Oyj's FCF Margin % or its related term are showing as below:
OHEL:NXTMH'
s FCF Margin % Range Over the Past 10 Years
Min: -303.46 Med: -74.65 Max: 2
Current: -2.63
During the past 13 years, the highest FCF Margin % of Nexstim Oyj was 2.00%. The lowest was -303.46%. And the median was -74.65%.
OHEL:NXTMH's FCF Margin % is ranked worse than 55.91% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: -0.505
vs OHEL:NXTMH: -2.63
The historical data trend for Nexstim Oyj's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OHEL:NXTMH vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, Nexstim Oyj's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexstim Oyj FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nexstim Oyj's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Nexstim Oyj's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nexstim Oyj (OHEL:NXTMH) has a FCF Margin % of -16.73% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nexstim Oyj and its competitors. According to the industry distribution chart, Nexstim Oyj ranks #454 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 55.9%.
Is Nexstim Oyj's FCF Margin % too high?
Nexstim Oyj's current FCF Margin % is -16.73%. Based on the distribution chart, Nexstim Oyj ranks #454 out of 812 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nexstim Oyj has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nexstim Oyj's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nexstim Oyj ranks #454 out of 812 companies for FCF Margin %. This places Nexstim Oyj in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nexstim Oyj and its competitors. Nexstim Oyj's current FCF Margin % is -16.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexstim Oyj stock overvalued right now?
Based on GuruFocus' analysis, Nexstim Oyj (OHEL:NXTMH) is currently considered Modestly Overvalued. The stock's GF Value™ is €9.38, compared to a current price of €10.80 — trading 15.1% above its estimated fair value. The current FCF Margin % is -16.73%. Nexstim Oyj's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Nexstim Oyj (OHEL:NXTMH), the current FCF Margin % is -16.73% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nexstim Oyj (OHEL:NXTMH) Overvalued in 2026?
Based on GuruFocus' analysis, Nexstim Oyj stock appears to be overvalued.
The current stock price of €10.80 is trading 15.1% above its estimated GF Value™ of €9.38.
GuruFocus considers Nexstim Oyj to be Modestly Overvalued.
Key valuation signals for OHEL:NXTMH:
FCF Margin %: -16.73%
GF Value™: €9.38 vs. price of €10.80 (15.1% above fair value)
No single metric tells the full story. See the OHEL:NXTMH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nexstim Oyj is a Finnish medical technology company. It has developed a non-invasive brain-stimulation technology for navigated transcranial magnetic stimulation (nTMS), with sophisticated 3D navigation that provides accurate, personalized targeting of TMS to specific brain areas. The company's diagnostic business focuses on commercializing the NBS System 6, an FDA-cleared, CE-marked navigated TMS system for pre-surgical mapping of the brain's speech and motor cortices. Its therapy business sells the NBS System 6 for the treatment of depressive disorder in the United States, and for the treatment of depression, chronic neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb, in Europe. Geographically, the firm generates maximum revenue from North America.
61GF Score
Get the complete analysis for OHEL:NXTMH
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OHEL:NXTMH has been successfully added to your 
